News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
62,561 Results
Type
Article (1483)
Company Profile (10)
Press Release (61068)
Multimedia
Podcasts (1)
Webinars (1)
Section
Business (30197)
Career Advice (30)
Deals (4560)
Drug Delivery (9)
Drug Development (7276)
Employer Resources (2)
FDA (1155)
Job Trends (1519)
News (41117)
Policy (2189)
Tag
Academia (119)
Adcomms (2)
Allergies (3)
Alliances (2029)
ALS (4)
Alzheimer's disease (93)
Antibody-drug conjugate (ADC) (9)
Approvals (1185)
Artificial intelligence (18)
Autoimmune disease (2)
Automation (1)
Bankruptcy (10)
Best Places to Work (1517)
Biosimilars (4)
Biotechnology (5)
Bladder cancer (23)
Breast cancer (47)
Cancer (313)
Cardiovascular disease (27)
Career advice (28)
Career pathing (3)
CAR-T (9)
CDC (6)
Cell therapy (25)
Cervical cancer (3)
Clinical research (6593)
Collaboration (52)
Compensation (28)
Complete response letters (1)
COVID-19 (164)
CRISPR (4)
C-suite (12)
Cystic fibrosis (12)
Data (400)
Depression (3)
Diabetes (49)
Diagnostics (676)
Digital health (3)
Drug discovery (11)
Drug pricing (11)
Drug shortages (1)
Duchenne muscular dystrophy (10)
Earnings (27567)
Editorial (2)
Employer resources (2)
Events (6643)
Executive appointments (23)
FDA (1380)
Frontotemporal dementia (2)
Funding (40)
Gene editing (6)
Gene therapy (17)
GLP-1 (96)
Government (265)
Guidances (111)
Healthcare (2058)
HIV (8)
IgA nephropathy (2)
Immunology and inflammation (7)
Immuno-oncology (1)
Indications (2)
Infectious disease (204)
Inflammatory bowel disease (7)
Influenza (8)
Intellectual property (6)
Interviews (2)
IPO (3523)
IRA (1)
Job creations (129)
Job search strategy (25)
Kidney cancer (3)
Labor market (8)
Layoffs (25)
Leadership (1)
Legal (372)
Liver cancer (7)
Lung cancer (43)
Lymphoma (37)
Machine learning (1)
Manufacturing (16)
MASH (15)
Medical device (1614)
Medtech (1614)
Mergers & acquisitions (1132)
Metabolic disorders (105)
Multiple sclerosis (14)
NASH (3)
Neurodegenerative disease (6)
Neuropsychiatric disorders (3)
Neuroscience (136)
NextGen: Class of 2025 (463)
Non-profit (224)
Now hiring (2)
Obesity (46)
Opinion (2)
Ovarian cancer (15)
Pain (1)
Pancreatic cancer (11)
Parkinson's disease (17)
Patents (15)
Patient recruitment (11)
Peanut (2)
People (1897)
Pharmaceutical (5)
Pharmacy benefit managers (1)
Phase I (1422)
Phase II (2681)
Phase III (2890)
Pipeline (601)
Policy (8)
Postmarket research (282)
Preclinical (451)
Press Release (3)
Prostate cancer (16)
Psychedelics (2)
Radiopharmaceuticals (25)
Rare diseases (44)
Real estate (179)
Recruiting (2)
Regulatory (1759)
Reports (11)
Research institute (112)
RSV (32)
Schizophrenia (6)
Series A (1)
Series B (4)
Sickle cell disease (7)
Special edition (2)
Spinal muscular atrophy (10)
Sponsored (1)
Startups (115)
Stomach cancer (1)
Supply chain (5)
Tariffs (1)
The Weekly (1)
Vaccines (82)
Venture capital (2)
Weight loss (29)
Women's health (2)
Worklife (2)
Date
Today (6)
Last 7 days (28)
Last 30 days (159)
Last 365 days (4083)
2025 (2111)
2024 (4607)
2023 (5165)
2022 (5643)
2021 (6209)
2020 (6002)
2019 (4128)
2018 (3249)
2017 (3453)
2016 (2102)
2015 (3050)
2014 (2344)
2013 (1300)
2012 (1452)
2011 (1842)
2010 (1624)
Location
Africa (38)
Alabama (6)
Arizona (30)
Asia (4489)
Australia (369)
California (863)
Canada (235)
China (51)
Colorado (48)
Connecticut (33)
Delaware (35)
Europe (8765)
Florida (142)
Georgia (34)
Idaho (2)
Illinois (73)
India (2)
Indiana (122)
Japan (23)
Kansas (50)
Kentucky (2)
Louisiana (4)
Maine (10)
Maryland (102)
Massachusetts (650)
Michigan (36)
Minnesota (63)
Missouri (6)
Montana (14)
Nebraska (3)
Nevada (8)
New Hampshire (9)
New Jersey (374)
New York (231)
North Carolina (181)
Northern California (428)
Ohio (22)
Pennsylvania (188)
Puerto Rico (1)
South America (90)
Southern California (337)
Tennessee (14)
Texas (98)
United States (3510)
Utah (29)
Virginia (12)
Washington D.C. (3)
Washington State (80)
Wisconsin (5)
62,561 Results for "59".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
June 13, 2025
·
7 min read
Press Releases
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) to 59 new, non-executive employees
May 16, 2025
·
3 min read
Press Releases
Cancer Therapeutics and Biotherapeutics Market Size to Expand USD 440.59 Bn by 2034
February 26, 2025
·
1 min read
Press Releases
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
April 17, 2025
·
9 min read
Press Releases
U.S. Vaccine Market Size to Surpass USD 59.77 Billion by 2034
February 20, 2025
·
1 min read
Press Releases
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
April 17, 2025
·
7 min read
RSV
Kennedy Follows RSV Recommendations of ACIP Members He Fired
Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are at risk of severe disease.
July 3, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Cell Culture Vessels Market to Reach $17.59 Billion by 2034, Driven by 15.18% CAGR Growth
February 13, 2025
·
1 min read
Press Releases
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
April 1, 2025
·
10 min read
FDA
GSK’s RSV Shot Wins Expanded FDA Approval for At-Risk Adults Aged 50 to 59
The FDA on Friday approved GSK’s application to use Arexvy to vaccinate adults aged 50 to 59 years who are at increased risk of developing severe respiratory syncytial virus.
June 10, 2024
·
2 min read
·
Tristan Manalac
1 of 6,257
Next
